Literature DB >> 10690400

Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.

T Saotome1, T Takagi, C Sakai, K Kumagai, J Tamaru.   

Abstract

Twenty-five patients with relapsed or refractory non-Hodgkin's lymphoma were treated by combination chemotherapy with irinotecan hydrochloride (CPT-11) and adriamycin (ADM): CPT-11, 25 mg/m2 on days 1 and 2; ADM, 40 mg/m2 on day 3. Nine (36%) of twenty-five patients achieved CR. Fairly good responses were seen in relapsed B-cell lymphomas (4 of 8 in diffuse large B-cell lymphoma and 2 of 2 in follicular lymphoma grade 1), and substantial responses in T-cell lymphomas (1 of 4 in peripheral T-cell lymphoma and 2 of 7 in adult T-cell leukemia/lymphoma). Leukopenia was frequent but tolerable, and diarrhea minimal. Combination chemotherapy with a reduced dose CPT-11 and ADM was useful in the treatment of relapsed non-Hodgkin's lymphoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10690400     DOI: 10.1023/a:1008368905546

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  3 in total

1.  Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.

Authors:  Tontanai Numbenjapon; Jianyi Wang; David Colcher; Thomas Schluep; Mark E Davis; Julienne Duringer; Leo Kretzner; Yun Yen; Stephen J Forman; Andrew Raubitschek
Journal:  Clin Cancer Res       Date:  2009-06-23       Impact factor: 12.531

2.  Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma.

Authors:  Junji Suzumiya; Hitoshi Suzushima; Kouichi Maeda; Seiichi Okamura; Atae Utsunomiya; Tunefumi Shibuya; Kazuo Tamura
Journal:  Int J Hematol       Date:  2004-04       Impact factor: 2.490

3.  Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours.

Authors:  X Chen; A M Oza; Z Kusenda; Q-L Yi; D Kochman; M J Moore; A J Davis; L L Siu
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.